The aim of this study was to investigate the influence of symptom duration on treatment response and on the correlation between improvements in patient reported outcomes ( PRO ) and objective inflammation in patients with axial spondylarthritis ( SpA ) treated with etanercept ( ETA ) or adalimumab ( ADA ) .